Compare · AZN vs REPH
AZN vs REPH
Side-by-side comparison of AstraZeneca PLC (AZN) and Recro Pharma Inc. (REPH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and REPH operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $546.72B, about 7915.3x REPH ($69.1M).
- AZN has hit the wire 24 times in the past 4 weeks while REPH has been quiet.
- AZN has more recent analyst coverage (25 ratings vs 1 for REPH).
- Company
- AstraZeneca PLC
- Recro Pharma Inc.
- Price
- $176.33-0.62%
- $2.05-3.30%
- Market cap
- $546.72B
- $69.1M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- 2014
- News (4w)
- 24
- 0
- Recent ratings
- 25
- 1
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Recro Pharma Inc.
Recro Pharma, Inc., a contract development and manufacturing organization, engages in the development, manufacturing, and packaging of oral solid dose drug products in the United States and internationally. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was incorporated in 2007 and is based in Malvern, Pennsylvania.
Latest AZN
- Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6 Trial
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial
- SEC Form 6-K filed by AstraZeneca PLC
- IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
- SEC Form 25-NSE filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
Latest REPH
- SEC Form SC 13G/A filed by Recro Pharma Inc. (Amendment)
- SEC Form SC 13G/A filed by Recro Pharma Inc. (Amendment)
- Lake Ryan David covered exercise/tax liability with 1,022 shares, decreasing direct ownership by 0.13% to 800,557 units (SEC Form 4)
- Enloe J David Jr was granted 196,474 shares, increasing direct ownership by 18% to 1,295,414 units (SEC Form 4)
- Lake Ryan David was granted 110,025 shares and covered exercise/tax liability with 37,453 shares, increasing direct ownership by 10% to 801,579 units (SEC Form 4)
- Lake Ryan David covered exercise/tax liability with 34,096 shares, decreasing direct ownership by 4% to 729,007 units (SEC Form 4)
- Lake Ryan David covered exercise/tax liability with 1,419 shares, decreasing direct ownership by 0.19% to 763,103 units (SEC Form 4)
- Lake Ryan David covered exercise/tax liability with 5,690 shares, decreasing direct ownership by 0.74% to 764,522 units (SEC Form 4)
- Lake Ryan David covered exercise/tax liability with 1,197 shares, decreasing direct ownership by 0.16% to 770,212 units (SEC Form 4)
- Recro Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits